To date, the majority of such agents being developed to treat metabolic diseases possess activity at the GLP-1R as the anchor pharmacophore but are also agonists for either the GIPR, the glucagon receptor, or both (7, 8). This evidence concerns the gene GLP1R and Other metabolic disease.